Can PET scans better predict lymphoma outcomes?
NCT ID NCT04333524
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study reviews PET scans from 496 people with marginal zone lymphoma to see how well the scans help with staging and predicting treatment response. Researchers will compare PET results with CT scans and other tests. The goal is to improve how doctors use PET imaging for this type of lymphoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors use PET scans more accurately to stage marginal zone lymphoma and predict how patients will respond to treatment.
- What could go wrong
- This is a retrospective analysis of existing scans, not a new treatment trial. It may not lead to immediate changes in care, and results depend on the quality of previously collected data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
"G. Rodolico", AOU Policlinico Vittorio Emanuele
Catania, CT, 95123, Italy
-
A.O. Santa Maria di Terni
Terni, TR, 05100, Italy
-
A.O.U. Città della Salute e della Scienza di Torino
Torino, TO, 10126, Italy
-
AOU Federico II
Naples, 80131, Italy
-
AOU Policlinico "Paolo Giaccone"
Palermo, PA, 90144, Italy
-
ASO SS. Antonio e Biagio e C. Arrigo
Alessandria, AL, 15121, Italy
-
AUSL IRCCS Reggio Emilia
Reggio Emilia, 42123, Italy
-
Azienda Ospedaliera - Ospedale di Circolo e Fondazione Macchi di Varese
Varese, VA, 21100, Italy
-
CHU de Dijon
Dijon, 21000, France
-
Fondazione IRCCS - Cà Granda Ospedale Maggiore Policlinico
Milan, MI, 20122, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, MI, 20133, Italy
-
Fondazione IRCCS Policlinico S. Matteo di Pavia
Pavia, PV, 27100, Italy
-
Hôpiteux Universitaires de Genève (HUG)
Geneva, Canton of Geneva, 1205, Switzerland
-
I.R.C.C.S. Istituto Oncologico Veneto
Padova, PD, 35128, Italy
-
IRCCS Centro di Riferimento Oncologico di Aviano
Aviano, PN, 33081, Italy
-
IRCCS Istituto Tumori "Giovanni Paolo II"
Bari, 70124, Italy
-
IUCT Oncopole Toulouse
Toulouse, 31100, France
-
Istituto Oncologico della Svizzera Italiana
Bellinzona, Canton Ticino, 6500, Switzerland
-
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS
Candiolo, TO, 10060, Italy
-
Ospedale Civile Spirito Santo Pescara
Pescara, PE, 65124, Italy
-
Ospedale Oncologico Businco
Cagliari, CA, 09121, Italy
-
Ospedale San Raffaele
Milan, MI, 20132, Italy
-
Ospedale degli Infermi
Ponderano, BI, 13875, Italy
-
Policlinico GB Rossi
Verona, VR, 37134, Italy
-
Saint Louis Hospital
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Smartwatches track hidden heart risk in blood cancer patients
- New drug combo aims to tackle Hard-to-Treat lymphoma